New therapeutics discovery and development for ocular diseases have been traditionally associated with a low probability of technical and regulatory success. The significant unmet medical needs for ocular diseases include…
New metrics and analytics capabilities enable informed decision making for biopharmaceutical clients PRINCETON, N.J., Dec. 13, 2021 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the…
Certara’s Japan team first met Dr. Kobuchi when he was studying Pharmacometrics at university for his PhD. He frequently attended our software training courses to learn Phoenix software. His proactive…
Sergiy Sirichenko summarizes industry metrics across many studies and sponsors to produce an overall picture of CDISC Controlled Terminology utilization.
PRINCETON, N.J.— November 8, 2021 — Certara, Inc, a global leader in biosimulation, today announced that it is launching a fellowship program for doctoral-level scientists from Africa, in partnership with…
Traditional mechanisms of drug action rely on the reversible, noncovalent interaction of a ligand with its biological target. On the other hand, a targeted covalent inhibitor (TCI) drug is designed…
How Certara supported a gene therapy manufacturer by using a selection of gateway and value indications as the foundation for the next phase of clinical development.
© 2025 Certara. All Rights Reserved. | Privacy policy
